Regeneron reinstated with an Underperform at BofA

BofA reinstated coverage of Regeneron (REGN) with an Underperform rating and $565 price target The firm calls Regeneron a “high-quality company,” with “lots to like generally,” but thinks Eylea, its lead franchise, erodes faster and harder than consensus. Despite a pullback in shares, the premium remains “too big,” especially given the firm’s below-consensus 2025 EPS view, the analyst added.